Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

Thromboxane A2 Synthetase Inhibitor Plus Low Dose Aspirin : Can It Be a Salvage Treatment in Acute Stroke Beyond Thrombolytic Time Window

  • An, Gyu-Hwan (Department of Neurosurgery, National Medical Center) ;
  • Sim, Sook-Young (Department of Neurosurgery, National Medical Center) ;
  • Jwa, Cheol-Su (Department of Neurosurgery, National Medical Center) ;
  • Kim, Gang-Hyeon (Department of Neurosurgery, National Medical Center) ;
  • Lee, Jong-Yun (Department of Neurology, National Medical Center) ;
  • Kang, Jae-Kyu (Department of Neurosurgery, Ajou University Hospital)
  • Received : 2010.12.16
  • Accepted : 2011.07.01
  • Published : 2011.07.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : There is no proven regimen to reduce the severity of stroke in patients with acute cerebral infarction presenting beyond the thrombolytic time window. Ozagrel sodium, a selective thromboxane A2 synthetase inhibitor, has been known to suppress the development of infarction. The antiplatelet effect is improved when aspirin is used together with a thromboxane synthetase inhibitor. Methods : Patients with non-cardiogenic acute ischemic stroke who were not eligible for thrombolysis were randomly assigned to two groups; one group received ozagrel sodium plus 100 mg of aspirin (group 1, n=43) and the other 100 mg of aspirin alone (group 2, n=43). Demographic data, cardiovascular risk factors, initial stroke severity [National Institute of Health Stroke Scale (NIHSS) and motor strength scale] and stroke subtypes were analyzed in each group. Clinical outcomes were analyzed by NIHSS and motor strength scale at 14 days after the onset of stroke. Results : There were no significant differences in the mean age, gender proportion, the prevalence of cardiovascular risk factors, stroke subtypes, and baseline neurological severity between the two groups. However, the clinical outcome for group 1 was much better at 14 days after the onset of stroke compared to group 2 (NIHSS score, p=0.007, Motor strength scale score, p<0.001). There was one case of hemorrhagic transformation in group 1, but there was no statistically significant difference in bleeding tendency between two groups. Conclusion : In this preliminary study, thromboxane A2 synthetase inhibitor plus a low dose of aspirin seems to be safe and has a favorable outcome compared to aspirin alone in patients with acute ischemic stroke who presented beyond the thrombolytic time window.

Keywords

References

  1. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. : Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24 : 35-41, 1993 https://doi.org/10.1161/01.STR.24.1.35
  2. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P : Antithromboticand thrombolytic therapy for ischemic stroke : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 : 630S-669S, 2008 https://doi.org/10.1378/chest.08-0720
  3. Bertele V, Falanga A, Tomasiak M, Dejana E, Cerletti C, de Gaetano G : Platelet thromboxane synthetase inhibitors with low doses of aspirin : possible resolution of the "aspirin dilemma". Science 220 : 517-519, 1983 https://doi.org/10.1126/science.6682245
  4. Brandt T, von Kummer R, Muller-Kuppers M, Hacke W : Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome. Stroke 27 : 875-881, 1996 https://doi.org/10.1161/01.STR.27.5.875
  5. Brott T, Bogousslavsky J : Treatment of acute ischemic stroke. N Engl J Med 343 : 710-722, 2000 https://doi.org/10.1056/NEJM200009073431007
  6. Cole DJ, Patel PM, Schell RM, Drummond JC, Osborne TN : Brain eicosanoid levels during temporary focal cerebral ischemia in rats : a microdialysis study. J Neurosurg Anesthesiol 5 : 41-47, 1993 https://doi.org/10.1097/00008506-199301000-00007
  7. Cross DT 3rd, Moran CJ, Akins PT, Angtuaco EE, Diringer MN : Relationship between clot location and outcome after basilar artery thrombolysis. AJNR Am J Neuroradiol 18 : 1221-1228, 1997
  8. Defreyn G, Deckmyn H, Vermylen J : A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2. Thromb Res 26 : 389-400, 1982 https://doi.org/10.1016/0049-3848(82)90311-5
  9. Del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M : PROACT : a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 29 : 4-11, 1998 https://doi.org/10.1161/01.STR.29.1.4
  10. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. : Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study : a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282 : 2003-2011, 1999 https://doi.org/10.1001/jama.282.21.2003
  11. Hacke W, Zeumer H, Ferbert A, Bruckmann H, del Zoppo GJ : Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 19 : 1216-1222, 1988 https://doi.org/10.1161/01.STR.19.10.1216
  12. Hallenbeck JM, Leitch DR, Dutka AJ, Greenbaum LT Jr, McKee AE : Prostaglandin I2, indomethacin and heparin promote postischemic neuronal recovery in dogs. Ann Neurol 12 : 145-156, 1982 https://doi.org/10.1002/ana.410120204
  13. Hankey GJ, Eikelboom JW : Aspirin resistance. Lancet 367 : 606-617, 2006 https://doi.org/10.1016/S0140-6736(06)68040-9
  14. Ichikawa K, Tazawa S, Hamano S, Kojima M, Hiraku S : Effect of ozagrel on locomotor and motor coordination after transient cerebral ischemia in experimental animal models. Pharmacology 59 : 257-265, 1999 https://doi.org/10.1159/000028328
  15. Kaplan S, Sauvage LR, Marcoe KF, Zammit M, Wu HD, Mathisen SR, et al. : A new combination therapy for selective and prolonged antiplatelet effect : results in the dog. Stroke 17 : 450-454, 1986 https://doi.org/10.1161/01.STR.17.3.450
  16. Lee SK, Min BK, Hwang SN, Suk JS, Choi DY : A clinical analysis of cerebral infarction. J Korean Neurosurg Soc 18 : 885-892, 1989
  17. Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, et al. : Early stroke treatment associated with better outcome : the NINDS rt-PA stroke study. Neurology 55 : 1649-1655, 2000 https://doi.org/10.1212/WNL.55.11.1649
  18. Matsuo Y, Kihara T, Ikeda M, Ninomiya M, Onodera H, Kogure K : Role of platelet-activating factor and thromboxane A2 in radical production during ischemia and reperfusion of the rat brain. Brain Res 709 : 296-302, 1996 https://doi.org/10.1016/0006-8993(95)01324-5
  19. Mellergard P, Bengtsson F, Smith ML, Riesenfeld V, Siesjo BK : Time course of early brain edema following reversible forebrain ischemia in rats. Stroke 20 : 1565-1570, 1989 https://doi.org/10.1161/01.STR.20.11.1565
  20. Mendioroz M, Fernandez-Cadenas I, Rosell A, Delgado P, DominguesMontanari S, Ribo M, et al. : Osteopontin predicts long-term functional outcome among ischemic stroke patients. J Neurol 258 : 486-493, 2011 https://doi.org/10.1007/s00415-010-5785-z
  21. Nishigaya K, Yoshida Y, Sasuga M, Nukui H, Ooneda G : Effect of recirculation on exacerbation of ischemic vascular lesions in rat brain. Stroke 22 : 635-642, 1991 https://doi.org/10.1161/01.STR.22.5.635
  22. Nosko M, Schulz R, Weir B, Cook DA, Grace M : Effects of vasospasm on levels of prostacyclin and thromboxane A2 in cerebral arteries of the monkey. Neurosurgery 22 : 45-50, 1988 https://doi.org/10.1227/00006123-198801000-00007
  23. Ohyama H, Hosomi N, Takahashi T, Mizushige K, Kohno M : Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia. Brain Res 902 : 264-271, 2001 https://doi.org/10.1016/S0006-8993(01)02354-X
  24. Roy MW, Dempsey RJ, Cowen DE, Donaldson DL, Young AB : Thromboxane synthetase inhibition with imidazole increases blood flow in ischemic penumbra. Neurosurgery 22 : 317-323, 1988 https://doi.org/10.1227/00006123-198802000-00007
  25. Sadoshima S, Ooboshi H, Okada Y, Yao H, Ishitsuka T, Fujishima M : Effect of thromboxane synthetase inhibitor on cerebral circulation and metabolism during experimental cerebral ischemia in spontaneously hypertensive rats. Eur J Pharmacol 169 : 75-83, 1989 https://doi.org/10.1016/0014-2999(89)90819-4
  26. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group : Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333 : 1581-1587, 1995 https://doi.org/10.1056/NEJM199512143332401
  27. Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ : Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am J Neuroradiol 14 : 3-13, 1993
  28. Yamashita T, Deguchi K, Nagotani S, Abe K : Vascular protection and restorative therapy in ischemic stroke. Cell Transplant 20 : 95-97, 2011 https://doi.org/10.3727/096368910X532800

Cited by

  1. Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers vol.10, pp.None, 2019, https://doi.org/10.3389/fphar.2019.01231